Marina Biotech this week presented early results from in vivo studies in rodent cancer models demonstrating effective delivery of a microRNA mimetic using the company's di-alkylated amino acid, or DiLA2, delivery system.
Marina Biotech this week presented early results from in vivo studies in rodent cancer models demonstrating effective delivery of a microRNA mimetic using the company's di-alkylated amino acid, or DiLA2, delivery system.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.